EFPIA position on clinical trial transparency
The biopharmaceutical industry believes that the disclosure of clinical trial results and appropriate sharing of clinical trial data is in the best interests of patients, clinicians, medical research and the biopharmaceutical industry. The industry is now widely-recognised as leading the way in clinical trial data sharing, adhering to the principles set out in joint EFPIA-PhRMA Principles for Responsible Clinical Trial Data Sharing including sharing patient level data. While we cannot comment on the specifics of on-going cases, responsible data sharing means supporting enhanced data sharing, while safeguarding patient privacy, respecting the integrity of national regulatory systems, and maintaining incentives for investment in biomedical research. As an industry we are committing to working with partners across the research community to develop a shared understanding and vision of where that balance lies.